Compare KE & BLSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KE | BLSM |
|---|---|---|
| Founded | 1961 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 462.1M | 483.4M |
| IPO Year | 2014 | 2026 |
| Metric | KE | BLSM |
|---|---|---|
| Price | $20.05 | $15.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $33.50 | ★ $35.40 |
| AVG Volume (30 Days) | ★ 184.9K | 146.7K |
| Earning Date | 11-04-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 66.18 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $1,431,378,000.00 | N/A |
| Revenue This Year | $7.87 | N/A |
| Revenue Next Year | $4.18 | N/A |
| P/E Ratio | $178.82 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.10 | $11.02 |
| 52 Week High | $32.00 | $27.99 |
| Indicator | KE | BLSM |
|---|---|---|
| Relative Strength Index (RSI) | 31.31 | 50.53 |
| Support Level | N/A | $12.93 |
| Resistance Level | $27.09 | $17.53 |
| Average True Range (ATR) | 1.43 | 1.76 |
| MACD | -0.75 | 0.27 |
| Stochastic Oscillator | 11.68 | 67.67 |
Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it has business units located in the United States, China, Mexico, Poland, Romania, and Thailand. The company derives maximum revenue from Mexico.
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.